美国烧伤治疗用组织工程产品的监管路径与要求
本文综述了美国 FDA 对烧伤治疗用组织工程产品(支架、细胞与生物活性分子组合)的多条监管路径,包括 BLA、510(k)、PMA 及 HCT/P 分类。文章说明了各路径所需数据的数量与类型差异,例如 BLA 需临床试验及 CBER 的安全有效性评估,并探讨了此类产品商业化的监管挑战。
要点
- 皮肤替代物按成分、来源和复杂性多样,监管归类随之不同
- BLA 需临床试验并由 CBER 评估安全性与有效性
- 获批生物制品还须按规定提交广告和宣传材料
核心结论
- 美国组织工程烧伤治疗产品可通过 BLA、510(k)、PMA 或 HCT/P 等多条路径获批准或许可
- 各监管分类的关键区别在于支持申报所需数据的数量与类型
研究设计与样本
- 综述,描述美国 FDA 对组织工程产品批准或许可的各监管路径及相关要求
- 检索范围原文未报告
主要发现
- 皮肤替代物可为含细胞或不含细胞,来源可为人类、动物或合成,复杂度可为单纯真皮或表皮及复合型
- BLA 要求开展临床试验并由生物制品评价与研究中心(CBER)评估安全性和有效性
- 适用的已批准生物制品须按法规提交广告与宣传材料
关键数值与推荐
- BLA:需临床试验及 CBER 安全有效性评估
- 510(k):适用于 Class I 和 Class II 器械
- PMA:适用于 Class III 器械
- HCT/P:人细胞、组织及细胞和组织基产品分类
临床怎么用
- 临床选用或开发烧伤用组织工程产品时,应依据其成分、来源与复杂度判断对应 FDA 监管路径
- 关注不同路径对临床前与临床数据的要求差异,以规划产品证据链
局限性
- 为叙述性综述,原文未报告系统检索策略与纳入标准
- 未提供具体产品的批准数据、样本量或疗效数值
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the burn treatment landscape, a variety of skin substitutes, human tissue-sourced products, and other products are being developed based on tissue engineering (ie, the combination of scaffolds, cells, and biologically active molecules into functional tissue with the goal of restoring, maintaining, or improving damaged tissue or whole organs) to provide dermal replacement, prevent infection, or prevent or mitigate scarring. Skin substitutes can have a variety of compositions (cellular vs acellular), origins (human, animal, or synthetically derived), and complexities (dermal or epidermal only vs composite). The regulation of tissue-engineered products in the United States occurs by one of several pathways established by the U.S. Food and Drug Administration, including a Biologics License Application (BLA), a 510(k) (Class I and Class II devices), Premarket Approval (Class III devices), or a human cells, tissues, and cellular and tissue-based products designation. Key differentiators among these regulatory classifications include the amount and type of data required to support a filing. For example, a BLA requires a clinical trial(s) and evaluation of safety and efficacy by the Center for Biologics Evaluation and Research. Applicable approved biological products must also comply with submission of advertising and promotional materials per regulations. This review provides a description of, and associated requirements for, the various regulatory pathways for the approval or clearance of tissue-engineered products. Some of the regulatory challenges for commercialization of such products for the treatment of burns will be explored.
引用
- Belsky K, Smiell J. Navigating the Regulatory Pathways and Requirements for Tissue-Engineered Products in the Treatment of Burns in the United States. J Burn Care Res. 2021. PMID: 33301575. doi:10.1093/jbcr/iraa210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。